ValiRx PLC Publication of VAL401 peer-reviewed article

TIDMVAL

ValiRx PLC

11 January 2019

VALIRX PLC

("ValiRx" or the "Company")

UPDATE ON VAL401

"Publication of article in the 'European Journal of Drug Metabolism and Pharmacokinetics"

"First published peer-reviewed journal article on VAL401 clinical trial results"

London, UK., 11 January 2019: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, is pleased to announce that further to its announcement on 18 December 2018, the Company notes that its peer-reviewed article, entitled: "Clinical Pharmacokinetics of a Lipid-Based Formulation of Risperidone, VAL401: Analysis of a Single Dose in an Open-Label Trial of Late-Stage Cancer Patients", has now been published online in the European Journal of Drug Metabolism and Pharmacokinetics and can be viewed via the following link: Dilly, S.J., Morris, G.S., Taylor, P.C. et al. Eur J Drug Metab Pharmacokinet (2019). https://doi.org/10.1007/s13318-018-00538-4

*** ENDS ***

For more information, please contact:

 
 ValiRx plc                                 Tel: [phone] 
                                             www.valirx.com 
 Dr Satu Vainikka, Chief Executive          Tel: [phone] 
 Tarquin Edwards, Head of Communications.   Tel: [phone] 
                                             364 
                                             [e-mail] 
 
 Novum Securities Limited                   Tel: [phone] 
  Colin Rowbury 
 
 

Notes for Editors

About ValiSeek

ValiSeek Limited ("ValiSeek") is a joint venture ("JV") company between ValiRx Plc and Tangent Reprofiling Limited, part of the SEEK Group. ValiSeek was formed to progress the drug VAL401 through its remaining preclinical development and towards Phase II trials for the treatment of lung cancer and other oncology indications.

About ValiRx

ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in "precision" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.

The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field.

ValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights. They originate or derive from World class institutions, such as Cancer Research UK and Imperial College.

Until recently, cancer treatments relied on non-specific agents, such as chemotherapy. With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients.

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

NRASFFFMSFUSESF

(END) Dow Jones Newswires

January 11, 2019 02:00 ET (07:00 GMT)